Biodex Corporation v. Loredan Biomedical, Inc.

946 F.2d 850, 20 U.S.P.Q. 2d (BNA) 1252, 1991 U.S. App. LEXIS 22986, 1991 WL 195759
CourtCourt of Appeals for the Federal Circuit
DecidedOctober 3, 1991
Docket91-1062
StatusPublished
Cited by174 cases

This text of 946 F.2d 850 (Biodex Corporation v. Loredan Biomedical, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Biodex Corporation v. Loredan Biomedical, Inc., 946 F.2d 850, 20 U.S.P.Q. 2d (BNA) 1252, 1991 U.S. App. LEXIS 22986, 1991 WL 195759 (Fed. Cir. 1991).

Opinion

CLEVENGER, Circuit Judge.

Biodex Corporation (“Biodex”) appeals the judgment of the U.S. District Court for the Eastern District of California entered on a jury verdict that found U.S. Patent *852 No. 4,691,694 (“694 patent”) invalid and U.S. Patent No. 4,628,910 (“910 patent”) not infringed by devices manufactured by defendants, Loredan Biomedical, Inc., and its chief executive, Malcolm Bond (collectively, “Loredan”). Biodex Corp. v. Loredan Biomedical, Inc., Civ-S-87-1132 (E.D.Ca. Oct. 2, 1990). We affirm.

I

Biodex is the assignee of both patents in suit which claim certain muscle exercise and rehabilitation devices. The 910 patent issued December 16, 1986. After notice of allowance, Biodex had filed a continuation-in-part application on September 15, 1986, which later matured into the 694 patent upon issuance on September 9, 1987. Bio-dex filed suit asserting that devices manufactured by Loredan infringed various claims of the patents.

At trial before a jury, Loredan contended, inter alia, that the 694 patent was invalid under 35 U.S.C. § 102(b) because the subject matter of the claimed invention had been offered for sale in the spring and summer of 1985, more than one year before the filing date. Biodex argued that the invention claimed in the 694 patent had not been satisfactorily tested so as to be safe for human use until after the critical date of September 15, 1985, and, therefore, could not have been on sale. On the 910 patent, Loredan argued that two terms in the asserted claims, written in means-plus-function language, did not read on the alleged devices because the corresponding structures found in the Loredan devices were not equivalent to the structures disclosed in the specification. Loredan contended that the inventor had expressly conceded this fact before the U.S. Patent and Trademark Office (“PTO”). Biodex responded, first, that the jury need only consider the plain language of the terms in question which read on the Loredan devices; second, that Loredan misconstrued the inventor’s concession during prosecution; and, third, that the structures in the accused devices were equivalents.

In its appellate briefs, Biodex recognizes that resolution of these issues required the jury to decide questions of fact. For instance, in its opening brief, Biodex contests that “the jury verdict of non-infringement of the ’910 patent was supported by substantial evidence.” In its reply brief, Biodex argues that the special verdict of invalidity of the 694 patent was not “supported by the evidence.” We read both references to evidentiary, support to concede that the verdicts were based upon factual determinations made by the jury. In any event, while we agree with Biodex’s initial contention that an ultimate conclusion as to an on-sale bar is a question of law, Barmag Barmer Masckinenfabrik AG v. Murata Mach., Ltd., 731 F.2d 831, 837, 221 USPQ 561, 565-66 (Fed.Cir.1984), the inquiry does not end there, as noted by Loredan. The many factors that enter into the “totality of the circumstances” underlying the legal conclusion of an on-sale bar involve exploration and resolution of questions of fact. Manville Sales Corp. v. Paramount Sys., 917 F.2d 544, 549, 16 USPQ2d 1587, 1591 (Fed.Cir.1990); U.S. Envtl. Prods., Inc. v. Westall, 911 F.2d 713, 716, 15 USPQ2d 1898, 1901 (Fed.Cir.1990); Shatterproof Glass Corp. v. Libbey-Owens Ford Co., 758 F.2d 613, 622-23, 225 USPQ 634, 639-40 (Fed.Cir.), cert. dismissed, 474 U.S. 976, 106 S.Ct. 340, 88 L.Ed.2d 326 (1985); Western Marine Elec., Inc. v. Furuno Elec. Co., 764 F.2d 840, 845, 226 USPQ 334, 337-38 (Fed.Cir.1985). Both parties agree that an operable physical embodiment of the invention was not in existence before the critical date. Therefore, the only question for the jury to resolve on the contested validity issue, which the parties treated as the determinative factor underlying validity, was whether the subject matter of the 694 patent was sufficiently tested by the spring and summer of 1985 so that the invention could be on sale. Evidence was provided that some testing had been undertaken prior to the critical date and the only disputed issue, then, was the adequacy of that testing, which is a question of fact. Cf. UMC Elec. Co. v. United States, 816 F.2d 647, 657, 2 USPQ2d 1465, 1472 (Fed.Cir.1987), cert. denied, 484 U.S. 1025, 108 S.Ct. 748, 98 L.Ed.2d 761 (1988). Similarly, “whether an *853 accused device is a section 112 equivalent of the described embodiment is a question of fact.” Durango Assoc., Inc. v. Reflange, Inc., 843 F.2d 1349, 1357, 6 USPQ2d 1290, 1295 (Fed.Cir.1988) (note omitted).

As permitted by Fed.R.Civ.P. 51, both parties requested and submitted various jury instructions. The district court, however, drafted its own instructions. Preserving its plain language argument, Bio-dex objected to the instructions on identifying equivalent structures to a claimed means expressed in functional language and on using the doctrine of prosecution history estoppel in determining the scope of protection under the doctrine of equivalents. Biodex contended that literal claim construction should be no different for a claim drafted under 35 U.S.C. § 112 ¶ 6 because the statute makes no “distinction” whether a claim uses “means-plus-function” language or not. Biodex requested but did not receive an additional instruction on application of the doctrine of prosecution history estoppel, which read, in pertinent part:

However, you should note that the doctrine of prosecution history estoppel has no applicability whatsoever if the plain language of the claims reads on an accused device for then infringement exists.

At the conclusion of testimony, Biodex orally moved for a directed verdict. Review of a transcript of that motion does not reveal a specific allegation that Loredan’s evidence in support of the contested validity or infringement issues was insufficient although judgment was requested on those issues as a matter of law. The district court never ruled upon the motion. The case was submitted to the jury with multiple special verdicts forms. In the verdicts, the jury found that all the asserted claims of the 694 patent were proved invalid and that none of the claims of the 910 patent were infringed by Loredan. The district court entered judgment on the jury verdicts. Biodex made no post-verdict motions either by renewing its motion for a directed verdict, moving for a new trial, or by moving for judgment non obstante veredicto (“JNOV”).

II

On appeal, Biodex contends that the failure to give the requested jury instruction was prejudicial error. Furthermore, Bio-dex contends that neither special verdict, of invalidity of the one patent nor of non-infringement of the other, was supported by substantial evidence. Loredan answers that the suggested jury instruction, while perhaps technically accurate, was misleading in the context of its defense that, “means-plus-function” language must be carefully construed.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Inline Plastics Corp. v. Lacerta Group, LLC
97 F.4th 889 (Federal Circuit, 2024)
In Re APPLE INC.
Federal Circuit, 2023
Eko Brands, LLC v. Adrian Rivera Maynez Enters.
946 F.3d 1367 (Federal Circuit, 2020)
Avid Technology, Inc. v. Harmonic, Inc.
812 F.3d 1040 (Federal Circuit, 2016)
Westerngeco L.L.C. v. Ion Geophysical Corp.
791 F.3d 1340 (Federal Circuit, 2015)
Loops, LLC v. Phoenix Trading, Inc.
594 F. App'x 614 (Federal Circuit, 2014)
Alcon Research, Ltd. v. Barr Laboratories, Inc.
745 F.3d 1180 (Federal Circuit, 2014)
Danisco U.S. Inc. v. Novozymes A/S
744 F.3d 1325 (Federal Circuit, 2014)
Verizon Services Corp. v. Vonage Holdings Corp.
503 F.3d 1295 (Federal Circuit, 2007)
Shanghai Meihao Electric, Inc. v. Leviton Manufacturing Co.
212 F. App'x 977 (Federal Circuit, 2007)
Eolas Technologies Inc. v. Microsoft Corp.
457 F.3d 1279 (Federal Circuit, 2006)
Yoon Ja Kim v. Sara Lee Bakery Group, Inc.
412 F. Supp. 2d 929 (N.D. Illinois, 2006)
Ventrassist Pty Ltd. v. Heartware, Inc.
377 F. Supp. 2d 1278 (S.D. Florida, 2005)
Bowling v. Hasbro, Inc.
403 F.3d 1373 (Federal Circuit, 2005)
Junker v. Eddings
396 F.3d 1359 (Federal Circuit, 2005)
Kao Corp. v. Unilever United States, Inc.
334 F. Supp. 2d 527 (D. Delaware, 2004)
SmithKline Beecham Corp. v. Pentech Pharmaceuticals, Inc.
261 F. Supp. 2d 1002 (N.D. Illinois, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
946 F.2d 850, 20 U.S.P.Q. 2d (BNA) 1252, 1991 U.S. App. LEXIS 22986, 1991 WL 195759, Counsel Stack Legal Research, https://law.counselstack.com/opinion/biodex-corporation-v-loredan-biomedical-inc-cafc-1991.